Allogene Therapeutics, Inc. — Form 8-K Summary
Reporting date: May 29, 2020. The filing reports initial Phase 1 ALPHA trial results for ALLO-501 and provides COVID-19-related operational updates. It does not contain quarterly or annual financial statements.
Business Context and Clinical Results
Allogene, in collaboration with Servier, is developing allogeneic CAR T therapies for relapsed/refractory non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma and follicular lymphoma.
- Twenty-three patients were enrolled and 22 received ALLO-501; one patient was removed before lymphodepletion because of acute renal failure from urinary obstruction.
- Nineteen patients had reached at least one month of assessment at the May 2020 data cutoff.
- Overall response rate was 63% and complete response rate was 37% among the 19 evaluable patients.
- Among 16 CAR T-naive patients, the overall response rate was 75% and complete response rate was 44%.
- With median follow-up of 3.8 months, nine of 12 responding patients remained in response at the data cutoff.
- Higher-dose ALLO-647 was associated with a 50% complete response rate, deeper lymphodepletion, and delayed host T-cell recovery.
Safety and Unusual Items
- No dose-limiting toxicities, graft-versus-host disease, or ICANS were observed.
- Cytokine release syndrome occurred in 32% of patients and was primarily mild to moderate; all events resolved within seven days.
- Reported adverse events of interest included infection, infusion reactions, and substantial Grade 3 and Grade 4 neutropenia.
- Four patients, or 18%, experienced serious adverse events, including infections, febrile neutropenia, hypotension, upper gastrointestinal hemorrhage, CMV reactivation, and hypokalemia.
- One patient who initially had a partial response and subsequently progressed achieved a complete response after retreatment with ALLO-501 and higher-dose ALLO-647; the filing classified the patient as a partial response in the reported table.
Financial Metrics, Liquidity, and Debt
The filing text does not provide clear values for revenue, profit or loss, cash flow, operating margins, debt, cash balances, liquidity, or other financial metrics. This Form 8-K is primarily a clinical and operational update.
Material Changes and Outlook
- Allogene plans to continue the ALPHA trial to further explore and optimize treatment.
- Enrollment has begun in the Phase 1 portion of the ALPHA2 trial evaluating next-generation ALLO-501A, which lacks the rituximab recognition domains found in ALLO-501.
- Servier resumed recruitment in the CALM and PALL trials after earlier COVID-19-related halts.
- Allogene continued enrolling patients in the ALPHA, ALPHA2, and UNIVERSAL trials, but COVID-19 was expected to affect new enrollment and patient follow-up.
- The company closed its headquarters, shifted administrative employees to remote work, limited onsite staffing, and experienced an interruption in construction of its Newark, California manufacturing facility.
- The timing and total impact of COVID-19-related delays on the business, preclinical studies, and clinical trials remained unknown.
Key Investor Verification Points
- Verify the small, early-stage ALPHA efficacy population, including only 19 patients with at least one month of assessment and limited median follow-up.
- Assess whether response durability improves or declines as additional follow-up becomes available.
- Monitor neutropenia, infections, serious adverse events, and other risks associated with lymphodepletion and CAR T treatment.
- Track enrollment, clinical data, and regulatory progress for ALLO-501, ALLO-501A, ALPHA, ALPHA2, and UNIVERSAL.
- Evaluate the operational and financial consequences of COVID-19-related trial delays and manufacturing construction interruptions.
- Review the collaboration and licensing arrangements with Servier and Cellectis, including Allogene’s exclusive U.S. rights.